Table 4.

Biomarker Analysis at Week 17

	Placebo (n = 25)	Dupilumab (n = 26)	SCIT (n = 26)	SCIT+dupilumab (n = 26)	SCIT+dupilumab vs SCIT Median Difference (95% CI), P value	Dupilumab vs Placebo Median Difference (95% CI), P value
sIgE
Median % change (LOCF)	−37.2	−16.9	81.3	−56.4	−134.6 (−205.51, −94.98), <0.0001	4.6 (−15.89, 29.59), 0.7314
Median absolute change (LOCF)	−1.110	−0.585	6.460	−2.990	−13.325 (−23.9400, −8.3600), <0.0001	0.740 (−0.9200, 3.3100), 0.3288
sIgG4
Median % change (LOCF)	19.0	0.0	1444.5	1896.3	335.3 (−551.47, 1746.55), 0.1231	0.0 (−30.77, 0.00), 0.4024
Median absolute change (LOCF)	0.050	0.000	1.705	3.550	0.665 (−0.7700, 3.2100), 0.1449	0.000 (−0.0800, 0.0000), 0.2734
sIgG
Median % change (LOCF)	0.0	0.0	216.1	454.6	159.5 (−43.94, 434.21), 0.0079	0.1 (−19.13, 23.81), 0.7295
Median absolute change (LOCF)	0.000	0.000	6.150	10.350	3.800 (−0.6000, 8.9000), 0.0112	0.050 (−0.5000, 0.8000), 0.7653
Log (sIgG4/sIgE)
Median change (LOCF)	0.310	0.235	0.745	1.720	0.840 (0.4500, 1.2700), <0.0001	−0.060 (−0.2300, 0.1200), 0.9551
Log (sIgG/sIgE)
Median change (LOCF)	0.190	0.130	0.180	1.105	0.830 (0.5400, 1.1300), <0.0001	−0.005 (−0.1900, 0.1800), 0.6032

Note: All P values reported are nominal.

Abbreviations: CI, confidence interval; LOCF, last observation carried forward; SCIT, subcutaneous immunotherapy; sIgE, timothy grass–specific immunoglobulin E; sIgG, timothy grass–specific immunoglobulin G: sIgG4: serum timothy grass–specific IgG4.